Overview:

Liquid biopsy is a minimally or non-invasive technology that detects molecular biomarkers using liquid sample without the need for costly or invasive procedures. These tests have considerable potential for early detection of cancer, treatment and recurrence monitoring, detection of genetic abnormalities in fetus, and graft rejection in transplantation patients. According to the estimation of National Cancer Institute, in the US around 1.6 million new cases of cancer are diagnosed, and 595,690 people have died due to cancer in 2016. According to the Canadian Cancer Society, 202,400 new cases of cancer and nearly 78,000 deaths are estimated in 2016. While in Europe 1.3 million people were diagnosed in 2015. Further, according to the study of World Health Organization, approximately 14 million new cancer cases were diagnosed and is expected to grow by about 70% over the next 2 decades.

The liquid biopsy market is booming due to the rising prevalence of cancer globally, advanced maternal age leading to growing chromosomal aberrations, and the increasing preference of non-invasive liquid biopsy tests over invasive tissue biopsy. The lack of sensitivity and specificity of liquid biopsy tests, high cost of the test with fewer reimbursement facilities, and the lack of trained professionals are some of the factors hampering the market growth. The markets in emerging countries are expected to grow at a rapid pace during the forecast period due to the increasing disease prevalence, healthcare awareness, and healthcare spending.

Market Analysis:

The Global Liquid Biopsy Market is estimated to witness a CAGR of 24.1% during the forecast period 2017–2023. The market is analyzed based on three segments, namely biomarker type, sample type, application, end-users, and regions.

Regional Analysis:

The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). The Americas is set to be the leading region for the liquid biopsy market growth followed by Europe. Asia Pacific and RoW are set to be the emerging regions.

Biomarker Type Analysis:

The global liquid biopsy market by biomarker type is segmented into circulating tumor cell (CTC), cell-free DNA (cfDNA), extracellular vesicles, and others. Cell-free DNA (cfDNA) segment is the largest segment in 2016 due to its wide range of application in prenatal testing, transplantation diagnostics, and oncology.

Sample Type Analysis:

The global liquid biopsy market by sample type is segmented into blood and others. Blood sample occupies the major market share in 2016 since most of the tests currently available in the market are blood-based tests.

Application Analysis:

The global liquid biopsy market by application is segmented into cancer and non-cancer applications. Cancer segment occupies the largest market share and is expected to be the fastest growing segment during the forecasted period. Cancer application is further segmented by cancer indication and clinical application.

End-users Analysis:

The global liquid biopsy market by end-users is segmented into hospital and reference laboratories, academic and research institutes, and others. Hospital and reference laboratories occupied a major share of liquid biopsy market in 2016 due to the increasing volume of test samples outsourced to this segment.

Key Players:

Biocept, Inc, F- Hoffmann-la Roche, Illumina, Inc, Natera Inc, Trovagene Inc., Qiagen N.V., Laboratory Corporation of America Holdings, Beijing Genomics Institute, Guardant Health, Inc., Genomic Health, MDx Health SA, Guardant Health, Inc., Myriad Genetics, Inc., and other predominate & niche players.

Competitive Analysis:

Currently, cancer tests dominate the global liquid biopsy market. A lot of new players are concentrating on this market to provide ground-breaking test with high sensitivity, specificity, and less turnaround time. Major market players are acquiring small companies to enhance their product portfolio and strengthen their leadership position in the market. Apart from this, the major players are launching innovative tests to have an upper hand in the market. For instance, in September 2017, Biocept launched Liquid Biopsy test for NRAS mutations.

Benefits:

The report provides complete details about the usage and adoption rate of liquid biopsy tests in various applications and regions. With that, key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, government initiatives toward the test adoption in the upcoming years along with the details of commercial tests available in the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in specific verticals to analyze before investing or expanding their business in this market.

Key Stakeholders:

1     INDUSTRY OUTLOOK  

1.1        Industry overview

1.2        Total addressable market

1.3        Industry Trends

2     Report Outline

2.1        Report Scope

2.2        Report Summary

2.3        Research Methodology

2.4        Report Assumptions

3     Market Snapshot 

3.1        Market Definition – Infoholic Research

3.2        Importance of Liquid biopsy

3.3        Complications of Liquid biopsy

3.4        Segmented Addressable Market (SAM)

3.5        Industry Trends

3.6        Related Markets

3.6.1     Cell-free DNA testing market

3.6.2     Transplantation Diagnostics Market

3.6.3     Point Of Care Diagnostics Market

4     Market Outlook  

4.1        Overview

4.2        Regulatory framework

4.3        Funding scenario

4.4        Market segmentation

4.5        PEST Analysis

4.6        Porter 5(Five) Forces

5     Market Characteristics 

5.1        DRO – Global Liquid Biopsy Market Dynamics

5.1.1     Drivers

5.1.1.1    Rising Prevalence of Cancer globally

5.1.1.2    Growing preference of non-invasive liquid biopsy tests over invasive tissue biopsy

5.1.1.3    Advanced maternal age leads to growing incidence of babies with chromosomal aberrations

5.1.1.4    Growing emphasis on personalized medicine

5.1.2     Opportunities

5.1.2.1    Upsurge in healthcare spending and growing healthcare awareness in emerging countries

5.1.2.2    Advantages of exosomes as source materials

5.1.2.3    Agreements and collaborations

5.1.3     Restraints

5.1.3.1    Lack of specificity and sensitivity of liquid biopsy tests

5.1.3.2    High charge of the test with less reimbursement facilities

6     Biomarker Types: Market Size and Analysis

6.1        Overview

6.2        Circulating tumor cell (CTC)

6.3        Cell-free DNA (cfDNA)

6.4        Extracellular vesicles

6.5        Others

7     Application: Market Size and Analysis 

7.1        Overview

7.2        Cancer application

7.2.1     Cancer application, By cancer type

7.2.1.1    Lung cancer

7.2.1.2    Breast cancer

7.2.1.3    Colorectal cancer

7.2.1.4    Prostate cancer

7.2.1.5    Melanoma

7.2.1.6    Others

7.2.2     Cancer application, By clinical application

7.3        Non-Cancer application

7.3.1     Prenatal testing

7.3.2     Transplantation diagnsotics

8     Sample type: Market Size and Analysis 

8.1        Overview

8.2        Blood

8.3        Others

9     End Users: Market Size and Analysis 

9.1        Overview

9.2        Hospitals and reference laboratories

9.3        Academic and research Institutes

9.4        Others

10   Regions: Market Size and Analysis

10.1     Overview

10.2     North America

10.2.1  Overview

10.2.2  United states

10.2.3  Canada

10.3     Europe

10.3.1  Overview

10.3.2  United Kingdom

10.3.3  Germany

10.3.4  France

10.3.5  Spain

10.4     APAC

10.4.1  Overview

10.4.2  India

10.4.3  China

10.4.4  Japan

10.5     Rest of the World

10.5.1  Overview

10.5.2  Brazil

10.5.3  Middle East

11   Competitive Landscape

11.1     Overview

12   Vendor Profiles 

12.1     Biocept, Inc.,

12.1.1  Overview

12.1.1  Business Focus

12.1.2  SWOT Analysis

12.1.3  Business Strategy

12.2     Natera, Inc.

12.2.1  Overview

12.2.2  Geographic Presence

12.2.3  Business Focus

12.2.4  SWOT Analysis

12.2.5  Business Strategy

12.3     Laboratory Corporation of America Holdings (LABCORP)

12.3.1  Overview

12.3.2  Business Unit

12.3.3  Geographic Presence

12.3.4  Business Focus

12.3.5  SWOT Analysis

12.3.6  Business Strategy

12.4     Illumina, Inc.,

12.4.1  Overview

12.4.2  Geographic Presence

12.4.3  Business Focus

12.4.4  SWOT Analysis

12.4.5  Business Strategy

12.5     Myriad Genetics

12.5.1  Overview

12.5.2  Business Unit

12.5.3  Business Focus

12.5.4  SWOT Analysis

12.5.5  Business Strategy

12.6     F.Hoffmann-La Roche Ltd

12.6.1  Overview

12.6.2  Business Unit

12.6.3  Geographic Presence

12.6.4  Business Focus

12.6.5  SWOT Analysis

12.6.6  Business Strategy

Companies to Watch For

12.7     CareDx, Inc

12.7.1  Overview

12.7.2  caredx: Recent Developments

12.8     Beijing Genomics Institute (BGI)

12.8.1  Overview

12.8.2  Beijing Genomics Institute: Recent Developments

12.9     MDxHealth SA

12.9.1  Overview

12.9.2  MDxHealth: Recent Developments

12.10  Exosome Diagnostics

12.10.1 Overview

12.10.2 Exosome Diagnostics: Recent Developments

12.11  QIAGEN NV

12.11.1 Overview

12.11.2 Qiagen NV: Recent Developments

12.12  Agena Bioscience

12.12.1 Overview

12.12.2 Agena Bioscience: Recent Developments

12.13  LifeCodexx AG

12.13.1 Overview

12.13.2 LifeCodexx AG: Recent Developments

12.14  Quest Diagnostics

12.14.1 Overview

12.14.2 Quest Diagnostics: Recent Developments

12.15  Guardant Health

12.15.1 Overview

12.15.2 Guardant Health: Recent Developments

12.16  Angle plc

12.16.1 Overview

12.16.2 Angle PLC: Recent Developments

12.17  Menarini-silicon Biosystems

12.17.1 Overview

12.17.2 Menarini-Silicon Biosystems: Recent Developments

12.18  Inivata Limited

12.18.1 Overview

12.18.2 Inivata Limited: Recent Developments

12.19  Personal Genome Diagnostics

12.19.1 Overview

12.19.2 Personal Genome Diagnostics: Recent Developments

12.20  Trovagene

12.20.1 Overview

12.20.2 Trovagene, Inc.: Recent Developments

Annexure  

Abbreviations